King of Prussia, PA & Berkeley Heights NJ, Jan 00, 2021 – Global biotherapeutics leader CSL Behring announced today the signing of a $10 million agreement with Axtria Inc. to deploy the Axtria DataMAx™ cloud software platform to fully digitize commercial data operations around the world, encompassing more than 60 drug brands in over 70 global markets.
"Axtria DataMAx™ will give us a truly robust global commercial data foundation to inform every strategic business decision impacting our commercial performance," said Mark Ridge, Vice President of Commercial Operations, CSL Behring. "We look forward to collaborating with Axtria to provide us a world-class commercial data technology infrastructure that will keep us competitively ahead in delivering the therapy solutions patients need anywhere we operate in the world."
CSL Behring will leverage Axtria DataMAx™ to integrate its global commercial data into one centralized scalable and extensible data warehousing ecosystem, including all native data platforms and solutions. As a result, anyone on international commercial operations teams can quickly access insights into such areas as drug sales performance by channel, the state of engagement with healthcare system providers, and digital vs. personal channel medical affairs activities.
"Streamlined data infrastructures and fast data-driven insights are needed more than ever for the life sciences industry post-COVID, " said Pradep Nair, Principal, Axtria. We designed Axtria DataMAx™ to address the needs of a large global pharmaceutical organization like CSL Behring. We are excited to be working with the CSL team to execute this digital transformation of their global commercial operations anchored on our Axtria DataMAx™ solution," added Nair.
The new Axtria DataMAx™ system will enable CSL Behring to bring products to market faster and harmonize commercial reporting processes. Overall, it will help manage patient journeys, better respond to patient data privacy requests, facilitate omnichannel customer engagement, and enhance ROI on marketing and sales expenditures while reducing CAPEX costs.
About CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company’s products are also used in cardiac surgery, burn treatment, and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 26,000 people and delivers its life-saving therapies to people in more than 70 countries. For inspiring stories about the promise of biotechnology, visit Vita CSLBehring.com/vita and follow us on Twitter.com/CSLBehring